Search
Pipotiazine
go.drugbank.com/drugs/DB01621ApprovedInvestigationalWithdrawnAmong the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. … It is used for the maintenance treatment of chronic non-agitated schizophrenic patients. Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation.
Linerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigational[A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).
Iophendylate
go.drugbank.com/drugs/DB01187ApprovedIophendylate, which was never shown to be safe, was initially introduced for use in small amounts (1-2cc) for locating spinal tumors. … Iophendylate is a mixture of isomers used as contrast medium, mainly for brain and spinal cord visualization. Iophendylate is a myelographic oil-ester (U.S. Patent 2,348,231).
Sodium bisulfite
go.drugbank.com/drugs/DB14015ApprovedWithdrawnSodium bisulfite has been used externally for parasitic skin diseases and as a gastrointestinal antiseptic.
Isoxaflutole
go.drugbank.com/drugs/DB12938ApprovedWithdrawnBalance has been investigated for the treatment of Chronic Renal Failure and Peritoneal Membrane Disorder.
CMC 001
go.drugbank.com/drugs/DB05353InvestigationalCMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.
Umifenovir
go.drugbank.com/drugs/DB13609Investigational[A191475] It has been in use in Russia for approximately 25 years and in China since 2006. … Umifenovir is an indole-based, hydrophobic, dual-acting direct antiviral/host-targeting agent used for the treatment and prophylaxis of influenza and other respiratory infections.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseIbrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalApril 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. … [L12228] Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.[L43020]
Sebetralstat
go.drugbank.com/drugs/DB18305ApprovedInvestigationalSebetralstat is the first and only oral on-demand treatment for HAE, providing a convenient alternative to injectable therapies that have been challenging for patients to use [L53538, A274293]. … Food and Drug Administration approved sebetralstat on July 7, 2025, for treating acute HAE attacks in patients aged 12 years and older [L53533, L53538].
Clobetasone
go.drugbank.com/drugs/DB13158ApprovedClobetasone is a corticosteroid that is often employed topically as a treatment for a variety of conditions such as eczema, psoriasis, various forms of dermatitis, and also for certain ophthalmologic conditions